

CURRICULUM VITAE

WILLIAM W. STORMS, M.D.

PROFESSIONAL INFORMATION

Office: The William Storms Allergy Clinic
1625 Medical Center Point, Suite 190
Colorado Springs, CO 80907
P: 719-955-6000
F: 719-955-9595

E-Mail Address: sneezedoc@stormsallergy.com

PRESENT ACADEMIC RANK & OTHER POSITIONS

Clinical Professor of Medicine, University of Colorado Health Sciences Center,
Denver, Colorado
Practicing Allergist, Colorado Springs, CO, 1975 to present
Principle Investigator, Storms Clinical Research Institute, Colorado Springs, CO, 2005 to present
Member of Sports Medicine Committee of the U.S. Olympic Committee 1997 to present
IRB member, United States Olympic Committee, 1997 to present
National Asthma Education and Prevention Program Coordinating Committee, (NHLBI
Asthma Guidelines) 1998 to present

EDUCATION

University: Northwestern University, Evanston, Illinois, B.A. Degree, 1964
Medical School: University of Wisconsin Medical School, Madison, Wisconsin,
M.D. Degree, 1968
Internship: San Francisco General Hospital, San Francisco, California,
1968-69
Residency: Internal Medicine Residency; University of Wisconsin Hospital,
Madison, Wisconsin, 1969-70, 1972-73
Fellowship: Allergy and Immunology; University of Wisconsin Hospital, Madison,
Wisconsin, 1973-75

BOARD CERTIFICATION

American Board of Internal Medicine, 1974
American Board of Allergy and Immunology, 1975
Recertification: American Board of Allergy and Immunology, 1987

MEDICAL LICENSURE Available upon request

SOCIETY MEMBERSHIPS

Fellow, American College of Physicians
Fellow, American Academy of Allergy, Asthma and Immunology
Fellow, American College of Allergy, Asthma and Immunology
Fellow, American College of Chest Physicians
Western Society of Allergy and Immunology
American Thoracic Society
Colorado Allergy Society
European Respiratory Society
Colorado Medical Society
European Academy of Allergology and Clinical Immunology

MEMBERSHIP ON COMMITTEES; OFFICES HELD

Board of Regents Member, American College of Allergy and Immunology, 1990 to 1993
President, Colorado Allergy Society, 1990-92
President, Western Society of Allergy and Immunology, 1987-88
Chairman, Public Relations Committee, American College of Allergy and Immunology, 1988
Chairman, Bylaws Committee, Penrose Hospital, Colorado Springs, 1985 to 1988
Chairman, American Academy of Allergy and Immunology Sports Medicine Committee, 1994-97
Steering Committee, American College of Chest Physicians Section on Allergy and Clinical Immunology, 1997 to 2003
El Paso County Medical Society Delegate to the Colorado Medical Society, 1989 to 1996
Advisory Board Member of Strategic Institute, a CME provider, Vienna, Virginia, 1996 to 2003
Member of the Steering Committee of the Aspen Allergy Conference 1997 to 2006

MEDICAL JOURNAL EDITORIAL BOARDS

Associate Editor for Medicine and Science in Sports and Exercise, 2004 to present
Associate Editor for Journal of Asthma, 1992 to present
Annals of Allergy, Asthma and Immunology, Editorial Board 1993 to 1998
Pediatric Rounds Newsletter, Editorial Board 1996 to 2000
American Journal of Medicine and Sports, Editorial Board 2001 to present
Reviewer for ADIS International Medical Journals
Reviewer for Journal of Allergy and Clinical Immunology
Reviewer for Annals of Allergy, Asthma and Immunology
Consultant and Member of Editorial Board for Nexcura, 2006 to present
Consultant and Reviewer for Consumer Reports/Consumers Union, April 2006 to present
Member of Editorial Board for Annals of Allergy, Asthma and Immunology, 1993 to 1998
Reviewer for Journal of Allergy and Clinical Immunology, New England Journal of Medicine, Chest

CONSULTANT

Abbott, Adams, Alcon Labs, Amgen, AstraZeneca, BMS, Boehringer, Consumer Reports/Consumers Union, Critical Therapeutics, Efficas, Exaeris, Genentech, Greer, GSK, Johnson & Johnson, Medpointe, Merck, Nexcura, Novartis, Sanofi-Aventis, Schering, Sepracor, Strategic Biosciences, Strategic Pharmaceutical Advisors, TEVA, TREAT Foundation, UCB

BOARD MEMBER

Strategic Biosciences, Strategic Pharmaceutical Advisors, TREAT Foundation

OTHER ACTIVITIES, ORGANIZATIONS, & AWARDS

Distinguished Fellow of the American College of Allergy, Asthma & Immunology. Presented at the awards convocation November 6, 1998 in Philadelphia, PA.
Bela Schick invited Lectureship, American College of Allergy, Asthma, & Immunology, Annual Meeting, San Francisco, November 1994
President, Cheyenne Mountain Zoological Park, 1991-92
Board of Trustees Member, 1987 to 1995
Vestry member, Chapel of Our Saviour Episcopal Church, Colorado Springs, 1978-81
Listed in "The Best Doctors in America" 1996 to present
Who's Who in Health and Medicine, 1989 to present
Student Volunteer, Project Hope, Colombia, South America, Summer 1967
Vice President, Broadmoor Ski Racing Academy, Inc., 1979-82
Volunteer Physician, Colorado Champ Camp (for children with asthma), 1985-95
Player of the Year, Broadmoor Golf Club, 2006
Career Achievement Award, University of Colorado School of Medicine, 2004
Cheyenne Mountain Country Club, Colorado Springs, Colorado, President and/or Board Member, 1982-94, 2002-10

PRESENTATIONS AT NATIONAL & INTERNATIONAL MEETINGS

1. "Late Adverse Reactions to Alternaria." Presented at the American Academy of Allergy Meeting, February, 1974
2. "Sch 1000 - An Anticholinergic Bronchodilator." Presented at the American College of Chest Physicians Meeting, November, 1974
3. "Procatamol Metered-Dose Inhaler in the Treatment of Asthma." Presented at the 41st Annual Congress of the American College of Allergists, February, 1985
4. "Albuterol Inhalant Solution for Asthma." Presented at the 41st Annual Congress of the American College of Allergists, February, 1985
5. "Ipratropium in the Treatment of Bronchial Asthma." Presented at the 41st Annual Congress of the American College of Allergists, Poster Session, February, 1985
6. "Azelastine in the Treatment of Asthma." Presented at the Academy of Allergy and Immunology, Poster Session, March, 1985
7. "Albuterol Inhalant Solution." Presented at the American College of Allergists meeting at the Schering symposium on New Horizons in Allergy, January 16, 1986
8. "Safety and Efficacy of Azelastine in Perennial Allergic Rhinitis." Presented at the American College of Allergists meeting, February, 1987
9. "Long-term Treatment of Asthma with Procatamol Metered-Dose Inhaler: A Two and One-Half Year Open-Label Study." Presented at the American College of Chest Physicians 53rd Annual Scientific Assembly, Poster Session, October 29, 1987
10. "Variability of Tree Pollination over 5 Years." Presented at the American College of Allergy and Immunology, November 15, 1987

PRESENTATIONS AT NATIONAL & INTERNATIONAL MEETINGS (cont.)

11. "SCH 434 (loratadine 5 mg plus pseudoephedrine 120 mg) Versus Components in the Treatment of Seasonal Allergic Rhinitis." Presented at the Forty-fourth Annual Meeting of the American Academy of Allergy and Immunology, March, 1988
12. "Once-A-Day Triamcinolone Acetonide (TA) Nasal Aerosol is Effective for Perennial Allergic Rhinitis." Presented at the Forty Fifth Annual Convention of the American College of Allergy and Immunology, November, 1988
13. "Ipratropium Bromide (Atrovent); Clinical Usage in Asthma." Presented at a symposium at the 46th Annual Meeting of the American College of Allergy and Immunology, November, 1989
14. "Update on New Advances in the Therapy of Allergic Rhinitis." Presented at a symposium at the American College of Allergy and Immunology Meeting, November, 1990
15. "Allergic Rhinitis" Washington University Symposium on Allergic Disease, St. Louis, November 1990
16. "A Once-A-Day Nasal Steroid (Nasacort - triamcinolone acetonide) is Effective Therapy for Perennial Allergic Rhinitis." Presented at the Ninth Annual Aspen Allergy Conference, July 23-27, 1991, Aspen, Colorado
17. "New Therapeutic Approaches to Allergic Rhinitis," American Academy of Allergy and Immunology, March 1992; Orlando, Florida
18. "Lipoxygenase and Leukotriene Inhibitors." Presented at the 1992 American College of Allergy and Immunology Symposium entitled "A New Age In the Therapy of Allergic Diseases," November 18, 1992.
19. "Sch 1000 - An Anticholinergic Bronchodilator." Presented at the Symposium on the Parasympathetic Pathway in Obstructive Lung Disease, Killarney, Ireland, 1974
20. "Azelastine in Bronchial Asthma." Presented at the Azelastine Symposium at the International College of Allergy and Clinical Immunology, Washington, D.C., October 1985
21. "Ipratropium in the Treatment of Asthma." Presented at the Symposium on Cholinergic Pathways in Lung Disease, Toronto, July 1986
22. "Bronchodilator Properties of Azelastine." Azelastine Workshop - American Lung Association Meeting, New Orleans, May 1987
23. "Azelastine: U.S. Experience in Seasonal and Perennial Rhinitis." Presented at the XIVth Congress of the European Academy of Allergology and Clinical Immunology, Berlin (West), September 1989
24. "Effect of Repeat Action Albuterol Sulfate (Proventil[®] Repetabs[®]) in Nocturnal Asthma," presented at the XIV International Congress of Allergology and Clinical Immunology, Kyoto, Japan, October 1991

PRESENTATIONS AT NATIONAL & INTERNATIONAL MEETINGS (cont.)

25. "The Effect of Repeat Action Albuterol Sulfate Tablets (Proventil[®] Repetabs[®]) in the Treatment of Nocturnal Asthma," presented at the Fifth International Conference on Chronobiology, Amelia Island, Florida, July 16, 1992
26. "Rationale for the Use of Antihistamines in Allergic Rhinitis," International Symposium of Infection and Allergy of the Nose, Seoul, Korea, October 8-11, 1993
27. "Fluticasone Nasal Spray: Comparator Studies in Allergic Rhinitis," European Academy of Allergy and Immunology, Stockholm, Sweden, June 1994
28. Moderator and Discussant, Interesting Case Symposium, American College of Allergy, Asthma & Immunology, Annual Meeting, San Francisco, CA, November 1994
29. Co-Chairman of the Olympic Exercise Asthma Symposium, Colorado Springs, CO, December 2-4, 1994
30. "Diagnosis and Treatment of Asthma." Lecture at the American Academy of Family Physicians. Annual Meeting, Orlando, FL, September 1995
31. "Exercise Asthma in Athletes." Presented at the Eastern Allergy Conference, April 18, 1995
32. "Long-term budesonide therapy in severe asthma: A 2½ year open label study." Poster presentation, Aspen Allergy Conference, July 1995
33. "Asthma Quality of Life Surveys in an Office Setting," ACAAI Managed Care Conference, Washington DC, April 12, 1996
34. Chairman, United States Olympic Committee Conference on Asthma for Physicians, Coaches and Athletic Trainers, November 1996, U.S. Olympic Training Center, Colorado Springs, CO
35. Moderator and speaker, ACAAI Annual Meeting Saturday Morning Conference, San Diego, CA
36. Speaker, AAAAI Sunday Evening Symposium on the Treatment of Asthma, March 1998, Washington DC
37. Luncheon moderator "Treatment of Rhinitis and Its Effects on the Lower Airway", Sunday symposium at the AAAAI meeting, Washington DC, March 1998
38. Speaker on Exercise-Induced Asthma at the 1st Sports Medicine Conference of the Arab World, Kuwait University, Kuwait City, Kuwait, March 1998
39. Speaker at the International Congress of Pediatric Allergy & Immunology, Cordoba, Argentina, May 24-27, 1998 ("Safety and efficacy of montelukast in children: a review of clinical data"; "Improving control of asthma in the moderately severe asthmatic")
40. "The Profile of the Ideal Nasal Steroid" at the European Academy of Allergy and Clinical Immunology Meeting, Brussels, Belgium, July 1999

PRESENTATIONS AT NATIONAL & INTERNATIONAL MEETINGS (cont.)

41. "Exercise Induced Asthma", presented at Cornell Medical College Allergy Teaching Day, New York, NY, October 1999
42. "Asthma and Rhinitis", presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting, Chicago, IL, November 1999
43. "Exercise-Induced Asthma", presented at the American Academy of Allergy, Asthma and Immunology Meeting, San Diego, CA, March 2000
44. "Treatment of Vasomotor Rhinitis: Summary of Physicians Survey and Double-Blind Study of Azelastine in Vasomotor Rhinitis", presented at the European Academy of Allergy and Clinical Immunology, Lisbon, Portugal, July 2000
45. "Treatment of Allergic Rhinitis in Children", presented at the Weekend of the Nose Meeting, Prague, January 2001
46. Invited Lecturer, "Treatment of Exercise Asthma", National Association of Athletic Trainers Annual Meeting, July 2001
47. "Therapeutic Options for Non-allergic Rhinitis", European Academy of Allergy and Clinical Immunology, Berlin, Germany, May 2001
48. "What are the New Third Generation Antihistamines and What Do They Do", presented at Nose 2000, International Congress of Rhinology, Washington DC, September 2000
49. "Criteria for the Ideal Nasal Steroid", presented at the American Academy of Allergy, Asthma and Immunology Meeting, Seattle, WA, November 2000
50. "Relationship Between Allergic Rhinitis and Asthma", American Academy of Allergy, Asthma and Immunology Symposium, March 18, 2001
51. "The Relationship of Allergic and Non-allergic Rhinitis", Allergic Rhinitis Symposium at the European Academy of Allergy and Clinical Immunology, May 11, 2001
52. "Methods of Controlling Rhinitis", Allergic Rhinitis Symposium; American Academy of Allergy, Asthma and Immunology meeting, November 19, 2001
53. "Treatment of Allergic Rhinitis and Comorbid Conditions", Lecture at the Primed South Meeting, Florida, February 21, 2002
54. "Economic and Clinical Impact of Allergic Rhinitis", AAAAI Meeting, Allergic Rhinitis Symposium, March 3, 2002
55. "Diagnosis and Treatment of Exercise-induced Asthma", AAAAI Meeting, March 4, 2002
56. "The Link Between Allergic Rhinitis and Asthma", Primed West Meeting, Long Beach, California, April 5, 2002

PRESENTATIONS AT NATIONAL & INTERNATIONAL MEETINGS (cont.)

57. "Treatment of Allergic Rhinitis with Specific Reference to Non-Sedating Antihistamines", Lectures in Taiwan, April 19 - 21, 2002
58. "The Role of Leukotriene Antagonists in the Treatment of Asthma", Tokyo, Japan, August 31, 2002
59. "The Allergic March: The Progression of Allergy From Infancy to Adulthood", American College of Allergy and Immunology Meeting, San Antonio, TX, November 14, 2002
60. "The Use of Intranasal Steroids in the Treatment of Allergic Rhinitis", Rhinitis Symposium, ACAAI Meeting, San Antonio, TX, November 17, 2002
61. "Clinical Trials: Are These Our Patients?", American Academy of Allergy, Asthma and Immunology, Annual Meeting, Denver, CO, March 2003
62. "Allergies and Asthma in Athletes", US Olympic Committee Conference on the Athens Olympic Games 2004; Effects of Heat and Humidity, Colorado Springs, CO, September 2003
63. "Exercise-Induced Asthma in Athletes", USA Cycling Coaches Conference, Colorado Springs, CO, January 29, 2004
64. "Epidemiology and Natural History of Allergic Rhinoconjunctivitis", American Academy of Allergy, Asthma & Immunology meeting, San Francisco, CA, March 2004
65. "Pharmacologic Approaches to Addressing Daytime and Nighttime Symptoms of Allergic Rhinitis", American Academy of Allergy, Asthma and Immunology meeting, San Francisco, CA, March 2004
66. "Practical Considerations in formulating Upper Airway Topical Medications", American College of Asthma, Allergy & Immunology meeting, Boston, MA, November 2004
67. "What Constitutes a Successful Outcome in Mild Asthma", American Academy of Allergy, Asthma and Immunology meeting, Boston, MA, November 2004
68. "Recent Research on Antihistamines in the Upper and Lower Airways", American Academy of Allergy, Asthma and Immunology meeting, Miami, FL, March 3, 2006
69. "Allergic Rhinitis: The Burden of Disease", presented at the American Academy of Allergy, Asthma and Immunology meeting, San Diego, CA, February 2007
70. "Exercise-Induced Bronchospasm in Athletes: Are They Being Over-Treated", presented at the American Academy of Allergy, Asthma and Immunology meeting, San Diego, CA, February 2007
71. "A Real World Open-Label Multi-Center Single Group Study to Evaluate Patients' Reactions to Mucinex", poster session, American Academy of Allergy, Asthma and Immunology meeting, San Diego, CA, February 2007

PRESENTATIONS AT NATIONAL & INTERNATIONAL MEETINGS (cont.)

72. “An Evaluation of Olopatadine 0.2% in the Treatment of Ocular Allergies Resulting from Outdoor and Indoor Allergens: A Pooled Analysis”, American Academy of Allergy, Asthma and Immunology meeting, Dallas, TX, November 2007
73. “An open label multi-center single group study to evaluate patients’ reactions to single entity long-acting guaifenesin”, poster presentation at the Western Society of Allergy, Asthma, and Immunology Meeting, January 2008, W. Storms, M.A. Kaliner, M. Javidi, C. Efessiou, J. Farrar
74. “Advances in the diagnosis and treatment of exercise-induced asthma”, lecture at the American Academy of Allergy, Asthma, and Immunology, March 2008, Philadelphia, PA, W. Storms
75. “Four years experience with Omalizumab (Xolair), the anti-IgE therapy for severe asthma”, lecture at the European Academy of Allergy and Clinical Immunology in Barcelona, June 2008, W. Storms
76. “Why and How does Exercise Cause Asthma Symptoms: Lessons Learned from the 2008 Olympics”, presented at American Academy of Allergy, Asthma and Immunology meeting, March 2009

CLINICAL TRIALS PERFORMED AT THE RESEARCH CENTER

Ipratropium bromide inhaler for the treatment of asthma - various studies, 1975-1990
Flunisolide inhaler for the treatment of asthma - 1977
Taziflyline tablets in rhinitis - 1987
Albuterol inhalant solution for asthma - 1984
Ketotifen syrup for children in asthma - 1984-1987
Procaterol inhaler for asthma - various studies - 1984-1990
Alupent inhaler for children with asthma - 1985-1989
Triamcinolone nasal spray for the treatment of rhinitis - various studies, 1986-1991
Loratadine and loratadine decongestant tablet studies for the treatment of rhinitis - 1986 to 1995
Taziflyline tablets in rhinitis - 1987
Enprofylline tablets for asthma - 1987
Proventil Repetabs for asthma - 1987-1989, 1992
Budesonide inhaler for asthma and rhinitis - 1987, 1991-1995
Efficacy of azelastine in perennial allergic rhinitis - 1988
Intal MDI for asthma - 1988
MK 571 capsules for asthma - 1989
Accolate inhaler and tablet for asthma - 1989-1995
Auranofin capsules for steroid dependent asthmatics - 1989-1990
Nedocromil inhalant solution for children with asthma - 1990
Salmeterol inhaler for asthma - 1990-1995, 1997
SCH 37370 tablet for rhinitis - 1990-91
Azelastine nasal spray for rhinitis - 1990
Vancenase-AQ vs. Nasalcrom in allergic rhinitis (pediatric) - 1990
Triamcinolone nasal spray (Nasacort) in allergic rhinitis (pediatric) - 1990
Pemirolast - 1991
Oral ebastine for allergic rhinitis – 1991-1998
Formeterol in Asthma – 1992
MK-0591 for asthma - 1992-1993
Vanceril DS - 1992-1993

CLINICAL TRIALS PERFORMED AT THE RESEARCH CENTER (cont.)

Zileuton in Asthma - 1992, 1994, 1997
Fluticasone in Asthma and Rhinitis Adult and Pediatric - 1992-1995, 1997-2000, 2001
Albuterol Turbuhaler - 1993
CP-80633 Tablet for Asthma – 1993
RP-73401 in Asthma - 1993
Uniphyl versus Beclovent - 1993
Non-CFC Salbutamol – 1993
MK-0476 in adults & pediatrics for asthma – 1993-1999
Mometasone in Asthma and Rhinitis - 1993-1994, 1997-1998, 1999
rhu-IL-IR in Asthma - 1993-1994
rhu-IL-4R in Asthma – 1999, 2000, 2001
Ceftibuten in Sinusitis - 1993-1994
Azelastine in Asthma - 1993-1995
Cetirizine in Allergic Rhinitis – 1994, 1997-1998, 2000, 2001
HOE 140 in Asthma – 1994
Nasacort Prophylaxis in Allergic Rhinitis - 1994
PDA-641 Capsules in Asthma – 1994-1996
Terfenadine and Metabolite in Rhinitis - 1994
Non-CFC Beclomethasone - 1994-1995, 1997-1998
Patient Compliance with Bronchodilator Therapy in Asthma – 1994
Atrovent in Allergic Rhinitis - 1994-1995
Effects of Vancenase on Growth - 1994
M94-216 in adult asthma - 1995
Non-CFC Azmacort in adults with asthma - 1995
Accolate in pediatric patients with asthma – 1995-1998
Accolate in adults with asthma – 1995-1998
SB205312 in adults with allergic rhinitis - 1995
SB205312 in adults with asthma – 1995
SR 27417A in adults with asthma – 1995-1996
AA 2414 in adults with asthma – 1995
Budesonide nebulizing solution – 1995-1996
Atrovent nasal spray in adults with rhinitis – 1995
Fluticasone in sinusitis – 1996-present
BAYx7195 in adults with asthma – 1996
Double-strength beclomethasone nasal spray in adults with asthma and rhinitis – 1996
RPR 106541T in adults with asthma – 1996
D7193 in adults with asthma – 1996
RG50294 in adults with rhinitis – 1996
Non-CFC Intal in exercise-induced asthma – 1997
Fexofenadine in adults and pediatrics in rhinitis – 1994-1995, 1997, 2000, 2001
Fexofenadine in adult urticaria – 1996-1997
SB 207499 in adult COPD – 1997
Serevent in adult COPD – 1997-1998, 2000, 2001
Raxar in adult sinusitis – 1997-1998
Tiotropium in adult asthma – 1997
Norestemizole in allergic rhinitis – 1997
Zanamavir in influenza – 1998, 1999, 2000
Seratrodast in adult COPD – 1997
Seratrodast in adult asthma – 1996
MK-0966 in adults with osteoarthritis – 1997-1999, 2000, 2001

CLINICAL TRIALS PERFORMED AT THE RESEARCH CENTER (cont.)

MK-0663 in adults with osteoarthritis – 1998 to present
Salmeterol/fluticasone in COPD – 1998-1999
Azelastrine in vasomotor rhinitis – 1999
HMR 3647A in adult sinusitis – 1998-1999
Astra AR-C68397AA in COPD – 1998-1999, 2000-2001
Fluticasone versus zafirlukast in asthma – 1998-1999
Salmeterol/fluticasone in adult asthma – 1998-1999, 2000, 2001
Merck L-808,065 in adult asthma – 1998-1999
Desloratadine in adult rhinitis and asthma – 1999, 2000
Montelukast in adults with rhinitis and asthma – 1999, 2000
Effects of nasal fluticasone on growth – 1999-2000, 2001
Effects of Accolate on growth – 1999
Effects of Azmacort on growth – 1999
Lansoprazole in adults with asthma and GERD – 1999, 2000
Triamcinolone effects on growth – 1999-2000
Montelukast in exercise-induced asthma in adults and pediatrics – 1999-2000, 2001
Accolate in pediatric exercise-induced asthma – 1999-2000
Effect of Rhinocort on growth – 1999-2001
Albuterol metered dose solution in adult asthma 1999-2000
Montelukast versus beclomethasone on growth – 2000, 2001
Bay 19-8004 in adults with asthma – 2000
Tequin in adult sinusitis – 2000
Merck L-753099 in COPD – 2000
IV montelukast in acute asthma – 2000
Serevent in adult exercise-induced asthma – 2000-2001
Ciclesonide in adult and pediatric asthma – 2001
Anapatrilat in adult hypertension – 2001
Salamol Easi-Breathe device in adult asthma – 2001
SB207499 in COPD – 2001
Loteprednol exabonate nasal spray in adults with rhinitis – 2001
Levalbuterol nebulized in acute asthma – 2001
Advil Multi-Symptom Allergy Sinus in adult rhinitis – 2001
Budesonide aqueous nasal spray (Rhinocort Aqua) in children with PAR – 2000-2001
Oral montelukast sodium vs. inhaled fluticasone propionate in patients with mild persistent asthma – 2000-2002
Montelukast w/placebo & inhaled beclomethasone in pediatric patient's w/mild asthma -2000-02
Roflumilast in patients with asthma – 2001
PLT 3514 dietary supplement in asthmatic children ages 12 –17 years – 2001
Clinical effects of montelukast in patients with PAR – 2001-2002
Formoterol fumarate delivered by multi-dose dry powder inhaler – 2001-2002
Tecastemizole in subjects with SAR and concomitant asthma – 2001-2002
PLT 3514 dietary supplement in asthmatic children ages 6-11 years – 2001
Fexofenadine in subjects with PAR - 2002
IN537217 nasal spray in subjects with PAR – 2002
Tecastemizole in subjects with SAR - 2002
T.I.M.E. migraine study, Zomig – 2002
Symbicort vs. its mono-products in children (>6 years) and adults with asthma – 2002
Symbicort vs. its mono-products in adolescents (> 12 years) and adults with asthma – 2002
Levalbuterol and recemic albuterol – 2002-2003
Etoricoxib vs. diclofenac sodium in patients with osteoarthritis – 2002 - 2003

CLINICAL TRIALS PERFORMED AT THE RESEARCH CENTER (cont.)

Effect of L-454560 in adult patients with chronic asthma – 2002-2003

Pulmicort Respules and Pulmicort Turbuhaler in adolescents (12 years and older) and adults with moderate to severe asthma – 2003

Olopatadine nasal spray vs. placebo in adolescents and adults with PAR – 2003

Symbicort inhaler in adolescents and adults with asthma, 2003-2004

Montelukast in adolescents and adults with PAR, 2003-2004

Civamide cream in adults with OA of the knee, 2003-2004

Patanol ophthalmic solution in adolescents and adults with allergic rhinitis, 2004

Roflumilast versus placebo in adults with asthma, 2004

Formoterol inhalation solution in patients with COPD, 2004

Advair Diskus versus Serevent Diskus in subjects with COPD, 2004

Measures of asthma control in adolescents and adults with either Arg/Arg; Gly/Gly or Arg/Gly genotype, 2004

Ariflo versus placebo in subjects with COPD, 2004

Pulmicort Turbuhaler in asthmatic adults, 2004

QVAR MDI or BOI versus placebo in adults & adolescents on ICS for asthma, 2004

Astelin versus Zyrtec in patients with SAR, 2004

Efficacy of ciclesonide metered-dose inhaler in adults and adolescents with mild to moderate persistent asthma not treated with steroids - 2005

Safety and efficacy of MP03-36 in patients with seasonal allergic rhinitis – 2006

Safety and efficacy of MP03-33 in patients with seasonal allergic rhinitis - 2006

Safety and efficacy of BMS-512148 as monotherapy in subjects with type II diabetes mellitus are treatment naïve and have inadequate glycemic control on diet and exercise - 2006

Effect of Xolair on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma - 2006

Efficacy of fluticasone propionate aqueous nasal spray 200mcg qd versus montelukast 10 mg qd in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair Diskus 100/50 mcg bid or placebo bid - 2006

Safety and efficacy of ciclesonide applied as a nasal spray for two weeks in the treatment of seasonal allergic rhinitis in patients 6-11 years of age - 2006

Effect of Roflumilast on exacerbation rate in patients with COPD. A 52-week, double-blind study with 500 mg Roflumilast once daily versus placebo – 2006

Safety study for Olopatadine Nasal Spray, 2007 – 2008

A double-blind randomized, placebo-controlled parallel group, multicenter, dose-ranging study to assess the efficacy and safety of Ciclesonide HFA nasal aerosol in adult and adolescent patients 12-years and older with seasonal allergic rhinitis (SAR) – 2007

Active-controlled trial of the safety and tolerability of MP03-36 in patients with perennial allergic rhinitis, 2007 - 2008

A randomized, double-blind, placebo-controlled, multiple dose phase II study to determine the safety and efficacy of AMG317 in subjects with moderate to severe asthma, 2007 – 2008

Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 and MP03-33 compared to placebo in the patients with seasonal allergic rhinitis – 2007

A two week, randomized, double-blind study assessing the onset of effect questionnaire (OEQ) administered daily versus weekly in adult subjects (7 – 18-years of age) with mild to moderate asthma, receiving Symbicort after MDI 80/4.5mg x 2 actuations twice daily or budesonide HFA after MDI 80mg x 2 actuations twice daily – 2007

Randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily Triamcinolone acetonide (NASACORT AQ NASAL SPRAY 110mg) on the growth velocity of children, 3 to 9 years of age, with perennial allergic rhinitis, 2007 – 2008

CLINICAL TRIALS PERFORMED AT THE RESEARCH CENTER (cont.)

Safety and efficacy of Olopatadine Nasal Spray in patients, 12 and above, with perennial allergic rhinitis - 2007

Safety and efficacy of Dapagliflozin as monotherapy in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise – 2007

Safety and efficacy of Symbicort pMDI 160/4.5mg x 2actuation twice daily versus Budesonide inhalation powder DPI 180 mg x 2 inhalations twice daily, in African American subjects, age 12 and older, with asthma – 2008

Safety and efficacy of oral administration of two dose regimens of JNJ-26113100 in adults with moderate to severe asthma and to characterize the effects of JNJ-26113100 on potential biomarkers of disease – 2008

Safety and efficacy of MP29-02 nasal spray compared to placebo, Azelastine Hydrochloride nasal spray in the treatment of patients with seasonal allergic rhinitis – 2008

Safety and efficacy of Grass (Phleum Pratense) Sublingual tablet (SCH 697243) in adult subjects with a history of grass pollen induced rhinoconjunctivitis with or without asthma – 2008

Safety and efficacy of sublingual immunotherapy with SCH 697243 (Phleum Pratense) in children 5 to < 18 years of age with a history of grass pollen induced rhinoconjunctivitis with or without asthma – 2008

Safety and efficacy of TAK-491 compared with Valsartan and Olmesartan in subjects with essential hypertension – 2008

Safety and efficacy of SKY 006 FlutiForm HFA pMDI (250/10mcg twice daily) in adolescents and adult patients with moderate to severe asthma – 2008-2009

MEDA 4006 – randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis - 2009

Genentech – Phase IIIb multicenter, randomized, double blind, placebo-controlled study of Xolair in subjects with moderate to severe persistent asthma who are inadequately controlled with high-dose inhaled corticosteroids and long-acting beta-agonists - 2009

Novartis-CQAB149B2351- A randomized double-blind, controlled, parallel group, 12 week treatment study to compare the efficacy and safety of the combination of indacaterol 150mg once daily versus open label tiotropium 18mg once daily in patients with moderate to severe chronic obstructive pulmonary disease - 2009

A double-masked randomized parallel group comparison of seasonal allergic rhinitis treatment with olopatadine 0.6% and Azelastine 0.1% when treatments are used in combination with fluticasone propionate 50mcg nasal spray SMA-08-23 - 2009

A double-blind, randomized multicenter cross-over evaluation of the sensory attributes of Olopatadine 0.6% and Azelastine 137mcg nasal sprays in patients with allergic rhinitis (sensory II) - 2009

AstraZeneca - A two-week randomized, double-blind study assessing the onset of effect questionnaire administered daily versus weekly in African American subjects greater or equal to 18 years of age with mild to moderate asthma, receiving Symbicort pMDI 80/4.5mg x 2 actuations twice daily or budesonide HFA pMDI 80 mg x 2 actuations twice daily – 2009

PUBLICATIONS

1. Chloroform parties, Storms WW, JAMA 225:160-165, July 9, 1973.
2. Aerosol Sch 1000: an anticholinergic bronchodilator, Storms W, DoPico G, and Reed CE, Amer Review of Resp Dis, 111:149, April 1975.

PUBLICATIONS (cont.)

3. Alternaria IgG precipitins and adverse reactions, Busse WW, Storms WW, Crandal M, and Reed CE, *J Allergy Clin Immunol*, 57:367, April 1976.
4. Antibody-dependent cellular cytotoxicity in asthmatics, Flaherty DK, Martin JM, Storms WW, Kriz RJ, Surfus JE and Reed CE, *J Allergy Clin Immunol*, 59:48-53, 1977.
5. Occupational hypersensitivity lung disease, Storms WW, *J of Occupational Med*, 20:823-824, 1978.
6. Allergic reactivity of the Pikes Peak region, Storms WW, *Southern Med Journal*, 72:673-675, June 1979.
7. Miller moth asthma, Storms WW, Berry C, and Withee W, *Clin Allergy*, 11:55-59, January 1981.
8. Hay fever symptoms from the cotton of the cottonwood tree, Storms WW, *Ann Allergy*, 53:223-225, September 1984.
9. Albuterol nebulizer solution for the treatment of asthma, Storms WW, Hudson LD, DeGraff AC, Mendelson LM, Greenstein S, *Ann Allergy*, 55:779-782, December 1985.
10. Ipratropium bromide (Atrovent^R): A new anticholinergic bronchodilator for the treatment of asthma, Storms WW, *Immunol Allergy Practice*, Vol III, P 53-59, February 1986.
11. Bitolterol mesylate aerosol in adults with steroid-dependent asthma: A comparison with isoproterenol hydrochloride aerosol, Nathan RA, Bodman SF, Storms WW, Mingo TS, *Ann Allergy*, 56:494-499, June 1986.
12. Use of ipratropium bromide in asthma: Results of a multi-clinic study, Storms WW, Bodman SF, Nathan RA, Busse WW, Bush RK, Falliers CJ, O'Hollaren JD, and Weg JG, *Amer J Med*, 81:61-66 (suppl 5A), November 1986.
13. SCH: 434; A new antihistamine/decongestant for seasonal allergic rhinitis, Storms WW, Bodman SF, Nathan RA, Chervinsky P, Banov CH, Dockhorn RJ, Jarmoszuk I, Zeitz HJ, McGeady SJ, Pinnaas JL, Greenstein S, *J Allergy Clin Immunol*, June 1989, Vol 83, No.6:1083-1090.
14. Procaterol metered-dose inhaler: A multiclinic study evaluating the efficacy and safety in patients with asthma, Storms WW, Chervinsky P, Bell T, Kemp JP, Brandon ML, Reed CE, Siegel SC, Repsher L, *Ann Allergy*, 63:444-448, November 1989.
15. Evaluation of the safety and efficacy of multiple doses of Azelastine to adult patients with bronchial asthma over time, Tinkelman EG, Bucholtz GA, Kemp JP, Koepke JW, Repsher LH, Spector SL, Storms WW, vanAs A, *Am Rev Resp Dis*, 141:569-574, 1990.
16. Managing Allergic Rhinitis: Implications for the upper and lower airways, Kaliner MA, Beer DJ, Bone RC, Busse WW, Creticos PS, Gardiner LJ, Lillington GA, McFadden EF, Naclerio RM, Storms WW, Nelson HS, Pipkorn U, Raphael GD, Simons FE, Slavin RG, Toffel PH, Ziemniak JA, *J Resp Dis*, March 1991.

PUBLICATIONS (cont.)

17. Metaproterenol (AlupentTM) metered-dose inhaler in children 5-12 years of age, Storms WW, Bierman CW, Chai H, Dockhorn RJ, Eggleston P, Ellis EF, Feldman C, Fink JN, Hemstreet MP, Kniker WT, Knutsen A, Konig P, Mansmann H, Siegell S, Krantman H, Tinkelman D, Townley R, Wecker M, Jaeger J, *J Allergy*, 28:369-379, 1991.
18. The effect of repeat action albuterol sulfate (ProventilR Repetabs^R) in nocturnal asthma, Storms WW, Nathan RA, Bodman SF, Morris RJ, Selner JC, Greenstein SM, Zwillich CW, *J of Asthma*, 29(3):205-212, 1992.
19. Update on the outpatient treatment of asthma, Storms WW in Comprehensive Therapy, 18(3):31-36, 1992.
20. Hay Fever: What it is and what to do about it, Storms WW, *Asthma and Allergy* 1992, Healthline, Menlo Park, CA.
21. Effect of acute inhalation of albuterol on submaximal and maximal VO₂ and blood lactate, Fleck SJ, Lucia A, Storms WW, Wallach JM, Vint PF, Zimmerman SD, *Int J Sports Med*, 14(1993):239-243.
22. Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis, Welch MJ, Bronsky E, Findlay S, Pearlman D, Southern L, Storms W, Weakley S, *Clin Therapeutics*, 16(2),(1994):253-262.
22. Patient compliance with bronchodilator therapy in asthma, Storms, WW, *Current Therapeutic Research*, 55(9),(1994):1038-1046.
23. The Rationale For The Use of H₁-Receptor Antagonists, Storms, WW, *Am J Rhinol* 8;(1994):376.
24. The effects of albuterol on power output in non-asthmatic athletes, J.T. Lemmer, S.J. Fleck, J.M. Wallach, S. Fox, E.R. Burke, J.T. Kearney, W.W. Storms, *Int J Sports Med*, 16(1995):243-249.
25. Practice parameters for allergy diagnostic testing, Bernstein IL, Storms WW, *Ann Allergy*, 75(6):December (Part 11) 1995.
26. Corticoid-sparing effect of azelastine in the management of bronchial asthma, Busse WW, Middleton E, Storms W, Dockhorn RJ, Chu TJ, Grossman J, Weiler JM, Bronsky EA, Mansfield LE, Bell TD, Hemsworth GR, Perhach JL, D'Eletto TA, Dam A. *Am J Respir Crit Care Med*, 153 (1996):122-127.
27. Effect of allergy specialist care on the quality of life in patients with asthma, Storms B, Olden L, Nathan R, Bodman S. *Ann Allergy*, 75 (6):December (Part 1) 1995.
28. Evaluation of the topical versus systemic effects of triamcinolone acetonide aqueous (TAA) nasal spray in allergic rhinitis, Storms B, Procaccini RL, Smith JA, *J Allergy Clin Immunol*, Vol. 95, No. 1, part 2, pg. 197 (Abst. 223), January 1995.
29. Prophylactic use of topical triamcinolone acetonide nasal inhaler in patients with seasonal allergic rhinitis, Storms W, Bernstein D, LaForce C, Pearlman D, Proud D, Kagey-Sobotka A, Lim J, Creticos P, *J Allergy Clin Immunol*, Vol. 97, No. 1, Part 3, January 1996.

PUBLICATIONS (cont.)

30. Improving the treatment of nocturnal asthma: Use of an office questionnaire to identify nocturnal asthma symptoms, Storms WW, Nathan RA, Bodman SF, Byer B, *J of Asthma* 3(33):165-168(1996).
31. Clinical studies of the efficacy and tolerability of ebastine 10-20 mg once daily in the treatment of seasonal allergic rhinitis in the US, Storms WW, *Drugs*, 52:20-25 (suppl 1), 1996.
32. Management of sinusitis in the asthmatic patient, Storms W, *Ann Allergy*, 77(1):July 1996.
33. The impact of managed care formularies on the practice of allergy-immunology, *Ann Allergy Asthma Immunol*, Vol 77, No.1:4-5 (1996).
34. Efficacy of triamcinolone acetonide aerosol nasal inhaler in children with perennial allergic rhinitis, Storms WW, Southern DL, et.al, *Ped Asthma, All & Immunol*, Vol 10, No.2: 59-64 (1996).
35. Update on exercise-induced asthma, a report of the Olympic exercise asthma summit conference, Storms WW, Joyner DM, *Physician & Sports Medicine*, Vol 25, No.3: 45-55 (1997).
36. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires, Meltzer EO, Nathan RA, Selner JC, Storms W, *J Allergy Clin Immunol*, Vol 99:S815-9 (1997).
37. The effects of salmeterol on power output in non-asthmatic athletes, McDowell SL, Fleck SJ, Storms WW, *J Allergy Clin Immunol*, Vol 99, No.4: 443-449 (1997).
38. Prevalence of allergic rhinitis in the United States, Nathan RA, Meltzer EO, Selner JC, Storms W, *J Allergy Clin Immunol*, Vol 99, No.6-2: S808-814 (1997).
39. Allergic rhinitis: the patient's perspective, Storms W, Meltzer EO, Nathan RA, Selner JC, *J Allergy Clin Immunol*, Vol 99, S825-8 (1997).
40. The economic impact of allergic rhinitis, Storms W, Meltzer EO, Nathan RA, Selner JC, *J Allergy Clin Immunol*, Vol 99, S820-4 (1997).
41. Treatment of allergic rhinitis: effects of allergic rhinitis and antihistamines on performance, Storms WW, *Allergy & Asthma Proc*, Vol 18, No. 2: 59-61 (1997).
42. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. *Ann Allergy Asthma Immunol*, 1997;79:443-8.
43. Do Asthma medications enhance sports performance in athletes who do not have asthma? Storms WW. *All Resp Dis Sports Med*, Marcel Dekker, New York, 1997;389-398.
44. A practical approach to the diagnosis and management of allergic rhinitis. Storms WW. *Amer Journal of Integrated Health Care*, Vol 1, No. 2 (Winter):78-87 (1998).

PUBLICATIONS (cont.)

45. Clinical adverse effects of inhaled corticosteroids: Results of a questionnaire survey of asthma specialists. W Storms, C Theen, *Ann Allergy*, 80:391-4, May 1998.
46. Risk-benefit assessment of fluticasone propionate in the treatment of asthma and allergic rhinitis. W Storms, *J Asthma*, 35(4):313-336, 1998.
47. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Sorkness CA, LaForce C, Storms W, et al, *Clin Ther*, 1999; 21(2):353-367.
48. A comprehensive diagnostic approach to upper airway disease. W Storms, *J Allergy Clin Immunol*, 1998;101:S361-3.
49. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. R Dockhorn, D Aaronson, E Bronsky, P Chervinsky, R Cohen, R Ehtessabian, A Finn, J Grossman, W Howland, H Kaiser, D Pearlman, J Sublett, P Ratner, G Settignano, T Sim, W Storms, R Webb, K Drda, C Wood, *Ann Allergy Asthma Immunol*, 1999;82:349-359.
50. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. E McFadden, T Casale, T Edwards, J Kemp, J Metzger, H Nelson, W Storms, M Neidl, *J Allergy Clin Immunol* 1999;104:46-52.
51. Exercise-induced asthma: diagnosis and treatment for the recreational or elite athlete. W Storms, *Med Sci Sports Exerc* 31:S33-38, 1999.
52. Double-blind, placebo-controlled study of single doses of chlorofluorocarbon (CFC) and CFC-free cromolyn sodium for exercise-induced bronchoconstriction. W Storms, *Current Therapeutic Res* 1999;60(12):629-37.
53. Atypical symptoms can mask the diagnosis. Exercise-induced asthma: making the diagnosis. W Storms, *J Respir Dis* 2000;21(8):491-494.
54. An idea bearing fruit. J Chapman, L Ford, R Miles, W Storms, J Winder, *Ann Allergy Asthma Immunol*, 2000;85:89[editorial].
55. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. W Storms, TM Michele, B Knorr, et al. *Clin Exp Allergy*, 2001;31(1):77-87.
56. Patient preference of inhaled nasal corticosteroids. W. Storms, *Allergy and Asthma Proc* Vol 22, No 6:S1-3, S27-28, Nov – Dec 2001.
57. New Rules for Olympic Athletes who take B2 Agonists: The IOC is Watching. J Weiler, W Storms, *Amer Journal of Medicine & Sports*, Vol IV, No II, March/April 2002.
58. Rethinking our approach to allergic rhinitis management. WW Storms, *Ann Allergy Asthma Immunol*, 2002;88(Suppl):30-35, April 2002.

PUBLICATIONS (cont.)

58. Allergens in the pathogenesis of asthma potential role of anti-immunoglobulin E therapy. W Storms, *Am J Respir Med* 2002; 1 (5):361-368.
59. Review of exercise-induced asthma. W Storms, *Med Sci Sports Exerc*, Vol. 35, No. 9;1464-1470, 2003.
60. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. W Storms, *Ann Allergy Asthma Immunol*, 2003;91:131-40, August 2003.
61. Unmet needs in the treatment of allergic asthma: potential role of novel biologic therapies. W Storms, *J Managed Care Pharm*, 2003;9 (6):534-43, November/December 2003.
62. Clinical trials: Are these your patients? W Storms, *J Allergy Clin Immunol* 2003;112:S107-11.
63. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. W Storms, *J Allergy Clin Immunol* 2004;114 (Suppl):S146-53, November 2004.
64. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. W Storms, P Chervinsky, AF Ghannam, et al., *Respir Med* 2004;98(11):1051-62, November 2004.
65. Cromolyn sodium: fitting an old friend into current asthma treatment. W Storms, MA Kaliner, *J Asthma* 2005;42(2):79-89, March 2005.
66. Asthma therapy: changing perspectives. W Storms, *J Resp Dis* 2005;26(10):S5-7, October 2005.
67. The use of anti-IgE strategies in asthma management: Applying emergent learning to the clinical practice setting, A CME Monograph. A Liu, W Storms, Oceanside Publications, February 2006.
68. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. A Weaver, RP Messner, W Storms, et al., *J Clin Rheumatol*, 2006;12:17-25.
69. Therapeutic options for reducing sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis. W Storms, B Yawn, L Fromer, *Cur Med Res Opin.*, 2007;23(9):2135-2146.
70. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. W Storms, *Expert Opin. Pharmacother.*, 2007;8(13):1-14.
71. A comparison of the effects of oral montelukast and inhaled Salmeterol on response to rescue bronchodilation after challenge. W Storms, P Chervinsky, AF Ghannam, et al, *Respir Med*, 2004;98(11):1051-62.
72. Challenges in the management of Exercise-induced asthma. W. Storms, *Expert Rev. Clin Immunol* 2009; 5(3): 261-269.
73. Exercise-Induced Bronchospasm, Storms WW. *Curr Sports Med Rep*, Vol 8, No 2, pp 45-46, March/April 2009.

PUBLICATIONS (cont.)

74. Guaifenesin in Rhinitis, Storms WW, Farrar JR, *Current Allergy and Asthma Reports*, 9(2):101-106, March 2009.

BOOK CHAPTERS

1. Storms WW, "Do asthma medications enhance sports performance in athletes who do not have asthma?", in *Allergic and Respiratory Diseases in Sports Medicine*, edited by John M. Weiler, Vol. II, 389-398, Marcel Dekker, New York, 1997.
2. Storms WW, "Allergies and Sports, in Asthma and Exercise", in *Human Kinetics*, edited by Rundell, Wilber and Lemanske, 2002.
3. Storms WW, "Allergy Diagnostic Procedures", in *Practical Allergy*, edited by Milgrom, Usatine, and Spector, Mosby, 2001.
4. Storms WW, "Allergic Rhinitis Caused by Inhalant Factors", in *Conn's Current Therapy*, edited by Rakel and Bope, 2003.
5. Storms WW, "Role of allergies in the provocation of exercise-induced asthma", in *Exercise-induced Asthma; Pathophysiology and Treatment*, edited by Rundell, Wilbur and Lemanske, 2002.
6. Storms WW, Milgrom EC, "Skin Testing", in *Practical Allergy*, edited by Milgrom, Usatine, Tan and Spector, 2004.
7. Storms WW, Milgrom EC, "Radioallergosorbent Testing (RAST)", in *Practical Allergy*, edited by Milgrom, Usatine, Tan and Spector, 2004.
8. Storms WW, "Asthma Associated With Exercise", in *Immunol Allergy Clin North Am* 2005;25(1):31-43.
9. Storms WW, Drazen JM, "Role of Leukotriene Antagonists in the Treatment and Prevention of Acute Asthma Exacerbations", in *Exacerbations of Asthma*, edited by Johnston and O'Byrne, 2006.

PUBLISHED ABSTRACTS

1. A Study of atopic dermatitis, adenylyl cyclase system and mitosis, Lee TP, Storms WW, Busse W, Reed CE, *J Allergy Clin Immunol*, 53:99, 1974 (abstr.)
2. Use of flow volume curves with air and helium-oxygen to evaluate pulmonary function in asthma, Storms WW, Bush R, and Reed CE, *J Allergy Clin Immunol* 57:252, 1976 (abstr.)
3. Intranasal immunization with attenuated live influenza vaccine in asthma, Storms WW, Dick EC, and Busse WW, *J Allergy Clin Immunol*, 58:284, 1976 (abstr.)

PUBLISHED ABSTRACTS (cont.)

4. Allergenicity of the cotton of the cottonwood tree, Storms WW, New Eng Allergy Proceedings, Vol. 5:151, Spring 1984 (abstr.)
5. Azelastine (AZEL) in the treatment of asthma, Storms W, Middleton E, Dvorin D, Kemp J, Spector S, Newton J, and Perhach J, J Allergy Clin Immunol, 75:167, January 1985 (abstr.)
6. Multicenter trial of procaterol aerosol metered-dose inhaler vs. placebo in patients with asthma, Storms W, Chervinsky P, Bell T, Brandon M, Reed CE, Repsher L, Siegel S, and Kemp J, J Allergy and Clin Immunol, 75:161, January 1985 (abstr.)
7. Procaterol metered-dose inhaler in the treatment of asthma, Storms W, Bodman S, Nathan R, Wilson JM, Ann Allergy, 54:338, April 1985 (abstr.)
8. Albuterol inhalant solution for asthma, Storms W, Bodman S, Nathan R, Greenstein S, Ann Allergy, 54:367, April 1985 (abstr.)
9. A group comparative study of the safety and efficacy of nedocromil sodium (Tilade) in reversible airways disease: A preliminary report, VanAS A, Chick TW, Bodman SF, Storms WW, Nathan RA, Selner JC, Koepke JW, Townley RG, Bewtra AK, Nair N, Kemp JP, Meltzer EO, Welch MJ, and Prenner BM, Eur J Respir Dis, 69 (suppl 147): 143-148
10. Comparison of procaterol and albuterol aerosols in patients with reversible obstructive airways disease, Chervinsky P, Beaupre A, Bell T, Bronsky E, Busse W, Campbell S, Falliers C, Mazza J, Pinnas J, Reed C, Repsher L, Stalein J, Schoenwetter W, Stevens P, Storms W, and Tashkin D, J Allergy and Clin Immunol, 79:201, January 1987 (abstr.)
11. Efficacy of azelastine in perennial allergic rhinitis, Meltzer E, Storms W, Pierson W, Cummins L, Perhach J, and Hemsworth G, J Allergy Clin Immunol, 79:205, January 1987 (abstr.)
12. Efficacy of azelastine (AZ) in perennial allergic rhinitis, Storms WW, Bodman SF, Nathan RA, Perhach JL, and Hemsworth GR, Ann Allergy, 58:281, April 1987 (abstr.)
13. Long-term treatment of asthma with procaterol metered-dose inhaler: a two and one-half year open label study, Storms WW, Bodman SF, and Nathan RA, Chest, 92:124S, August 1987 (abstr.)
14. WHR-5029 (triamcinolone acetonide nasal aerosol) in the treatment of seasonal ragweed allergic rhinitis (SRAR), Storms WW, Bodman SF, Nathan RA, Gawchick SM, Rooklin AR, Gorder JW, and Huber FJ, Ann Allergy, 60:166, February 1988 (abstr.)
15. Variability of tree pollination over 5 years, Storms WW, Nathan RA, Burdekin EA, Ann Allergy, 60:158, February 1988 (abstr.)
16. SCH: 434 (loratadine 5 mg plus pseudoephedrine 120 mg) versus components in the treatment of seasonal allergic rhinitis, Storms WW, Bodman SF, Nathan RA, Trochelman L, Greenstein S, J Allergy Clin Immunol, 18:173, January 1988 (abstr.)

PUBLISHED ABSTRACTS (cont.)

17. Evaluation of the safety and efficacy of long term use of multiple doses of Azelastine (AZ) in asthmatics, Tinkelman D, Bucholtz G, Kemp J, Repsher L, Spector S, Storms W, VanAs A, Koepke J, *J Allergy Clin Immunol*, January 1988 (abstr.)
18. Once-a-day Triamcinolone Acetonide (TA) nasal aerosol is effective for perennial allergic rhinitis (PAR), Storms W, Bronsky E, Findlay S, Pearlman D, Rosenbert S, Shapiro G, Southern L, Tinkelman D, Weakley S, Welch M, Zeitz H, Garcia J, Wilkinson D, *Ann Allergy*, 1:239, March 1989 (abstr.)
19. Azelastine: U.S. experience in seasonal and perennial rhinitis, Storms W, Hemsworth G, Freitag J, as published in *Allergologie*, September 1989 (abstr.)
20. Procatamol: Longer duration of action than albuterol (salbutamol) in a three month study, Beaupre A, Bell T, Boulet LP, Bronsky E, Busse W, Campbell SC, Chervinsky P, Falliers CJ, Mazza J, Pinnas JL, Tashkin DP, Reed CE, Repsher L, Schoenwetter W, Stablein J, Stevens P, Storms WW, *Chest*, 98:111S, August 1990
21. A comparison of the efficacy and safety of procatamol and albuterol in reversible obstructive airways disease, Mazza J, Beaupre A, Bell T, Boulet LP, Bronsky E, Busse W, Campbell SC, Chervinsky P, Falliers CJ, Pinnas JL, Tashkin DP, Reed CE, Repsher L, Schoenwetter W, Stablein J, Stevens P, Storms WW, *Chest*, 98:111S, August 1990
22. Inhibition by Aerolized ICI 204,219. LTD receptor agonist, of allergen-induced bronchoconstriction, Nathan RA, Storms WW, Bodman SF, Minkwitz MC, Glass M, *J Allergy Clin Immunol*, January 1991 (abstr.)
23. Once daily triamcinolone acetonide nasal spray is effective for the treatment of perennial allergic rhinitis, Storms W, Bronsky E, Findlay S, Pearlman D, Rosenberg S, Shapiro G, Southern L, Tinkelman D, Weakley S, Welch M, Zeitz H, Wilkinson D, McMahon S, Garcia J, *Ann Allergy* 66:329, April 1991
24. Effect of repeat action albuterol sulfate (Proventil^R Repetabs^R) in nocturnal asthma, Storms W, Morris R, Selner J, Zwillich C, Greenstein S, Colorado Springs, CO, Minneapolis, MN, Denver, CO, Hershey, PA, Kenilworth, NJ, *Allergy Immunol News*, Supplement 1-1991 (presented at the XIV International Congress of Allergology and Clinical Immunology, October 4, 1991) (abstr.)
25. Comparison of intranasal therapy with beclomethasone dipropionate (BDP) vs cromolyn sodium (CS) vs placebo (P) in children with seasonal allergic rhinitis (SAR), Orgel HA, Meltzer E, Welch M, Banov C, Georgitis J, Morris R, Pedinoff A, Storms WW, *J Allergy Clin Immunol*, 89:303, January 1992 (abstr.)
26. Efficacy of nedocromil nebulizer solution on asthma symptoms in children maintained on bronchodilators, Dockhorn RJ, Bronsky EA, Ginchansky EJ, Kraimer MJ, Pearlman DS, Ratner PH, Storms WW, *Amer Rev Respir Dis*, 145:743, April 1992
27. Azelastine nasal spray - a well controlled trial to assess its safety and efficacy in seasonal allergic rhinitis (SAR), Storms W, Grossman J, Pearlman D, Chervinsky P, Halverson P, Widlitz M, Freitag J, *Ann Allergy*, 68:108, January 1992 (abstr.)

PUBLISHED ABSTRACTS (cont.)

28. Albuterol and ergometry performance, Lucia A, Fleck SJ, Wallach JM, Vint PF, Storms WW, Zimmerman SD, *Medicine & Science in Sports and Exercise*, 24(5), May 1992 (abstr.)
29. Once-a-day ebastine is effective therapy for seasonal allergic rhinitis (SAR) in children, Storms WW, Garcia JD, Tobey RE, et al, *J Allergy Clin Immunol*, 91:197, January 1993
30. Nedocromil sodium (NED) 0.5% nebulizer solution improves asthma symptoms and pulmonary function in children. Dockhorn RJ, Ginchansky EJ, Pearlman DS, Ratner PH, Storms WW, *Ann Allergy*, 72:78, January 1994.
31. Fluticasone Propionate (FP), Triamcinolone acetonide (TAA) and Flunisolide (FLN) have similar effects on the HPA axis. Storms WW, Howland WC, Sorkness CA, LaForce C, Goldstein M, Lincourt WR, Rogenes PR, Schaberg AE, Edwards L, et al, *J Allergy Clin Immunol*, 99:S318, January 1997.
32. Efficacy of Astelin (azelastine) nasal spray in patients with vasomotor rhinitis. Storms WW, Matz J, Ratner P, *J Allergy Clin Immunol* 105:S205, January 2000.
33. The effect of fluticasone propionate nasal spray as adjunctive therapy to cefuroxime axetil on the resolution of radiographic evidence of an acute episode of sinusitis. Storms WW, Miller SD, Goldberg T, Henry D, Goode-Sellers ST, et al, *J Allergy Clin Immunol* 105:S206, January 2000.
34. Role of ocular symptoms in seasonal allergies and the effect of azelastine (Astelin[®]) nasal spray on ocular symptoms. Storms WW, LaForce C, Ratner P, *Ann Allergy Asthma Immunol* 96:188, January 2006.
35. A real world open-label multi-center single group study to evaluate patient's reactions to Mucinex. Storms WW, Kaliner M, Javid M, Efessiou C, Farrar J, *J Allergy Clin Immunol* 119(1):S229, January 2007.
36. Guaifenesin in Rhinitis, Storms WW, Farrar JR, *Current Allergy and Asthma Reports*, 9(2):101-106, March 2009 (abstr.)
37. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 μ g in the treatment of seasonal allergic rhinitis. Kaliner, MA, Storms, WW, Tilles, S, et al, *Allergy & Asthma Proceedings*, Vol 3, No 3, pp 255-262, May/June 2009 (abstr).